fbpx
QQQ
+ 1.31
311.52
+ 0.42%
DIA
-5.22
319.22
-1.66%
SPY
-2.36
384.73
-0.62%
TLT
+ 4.58
133.96
+ 3.31%
GLD
-4.03
169.90
-2.43%

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

November 2, 2020 10:24 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of October 26th – November 1st, 2020.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. Super-State Operator Red White & Bloom Featured on Stockhouse ‘Stock Talk’ Podcast

Following RWB’s IPO This Summer, the Company Has Executed Flawlessly Closing a Legendary String of Deals Including the Blockbuster High Times and Platinum Vape Deals

Rising cannabis Multi-State Operator (MSO) and new kid on the block Red White & Bloom (OTCQX:RWBYF) has quickly made a name for itself in a very competitive American Marijuana industry alongside big names like Trulieve (OTCQX:TCNNF), Curaleaf (OTCQX:CURLF), Green Thumb (OTCQX:GTBIF) and Cresco Labs (OTCQX:CRLBF).

READ FULL RWB ARTICLE

9. Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

The Recent Publication of the Potential of N-acetyl-cysteine (NAC) in the Treatment of COVID-191 Serves as Further Validation for Bucillamine

Revive Therapeutics (OTCPK: RVVTF) announced an update on the company’s U.S. FDA Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020.

READ FULL REVIVE ARTICLE

8. Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

The Research Will Be Led By Prof. Dr. Gerhard Gründer, the Only confirmed Scientist Developing a Study to Work With Psychedelics in Germany Since the 1970s

Havn Life Sciences (CSE:HAVN) announced the company has signed on to support ground-breaking research with the MIND Foundation on a study on depression and Psilocybin.

READ FULL HAVN LIFE ARTICLE

7. Green Thumb Industries Sells $79M Stake to Undisclosed Investor

The Shares Were Disposed of By an LLC Controlled By GTI Chief Executive Ben Kovler

Green Thumb (OTCQX:GTBIF) confirmed that an undisclosed institutional investor bought 5.5 million subordinated voting shares in the company for $79 million.

READ FULL GTII ARTICLE

6. MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

Post-Financing Cash Reserves of CAD $50.1m to Enable Continued Advancement of Diverse and Growing Clinical Trial Pipeline of Psychedelics

MindMed (NEO: MMED) (OTCQB:MMEDF) (FRA: BGHM) announced that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter’s over-allotment option. In connection with the offering, the company issued 27,381,500 units at a price of $1.05 for gross proceeds of $28,750,575. Canaccord Genuity Corp. acted as sole book-runner and underwriter in the Offering.

READ FULL MINDMED ARTICLE

5. 3 Fast-Growing Stocks Robinhood Investors Can’t Buy but Would Probably Love

Cue MC Hammer’s Hit “U Can’t Touch This” For Robinhood Investors Who Want to Scoop Up Shares of These Hot Stocks

Sorry, Robinhood investors. There are some stocks that you just can’t buy on the popular trading platform. Here are three fast-growing Pot Stocks that Robinhood investors can’t buy right now but would probably love: Curaleaf (OTCQX:CURLF), Green Thumb (OTCQX:GTBIF), Trulieve (OTCQX:TCNNF).

READ FULL ROBINHOOD INVESTORS ARTICLE

4. Field Trip Health Provides Update on FT-104, Its Next-Generation Psychedelic Molecule in Development

Results Confirm That Field Trip’s Novel Psychedelic Molecule is Similar in Potency to Psilocybin But With Shorter Duration of Psychoactivity Making it a Potentially Preferable Option for Psychedelic Therapies

Field Trip Health (OTC:FTRPF), the leader in the development and delivery of Psychedelic therapies, provided an update on its in-vivo and in-vitro studies on FT-104, its lead drug candidate.

READ FULL FIELD TRIP ARTICLE

3. Three Cannabis Stocks That Stifel Thinks Will Outperform

Stifel GMP Analyst Andrew Partheniou Says U.S. Cannabis Markets are Looking Better Than Previously Expected, Notably in Key Markets in Illinois, Pennsylvania, Massachusetts and California

That’s good news for at least three cannabis stocks with exposure to those states, says Partheniou, who on Monday delivered a report on the state of the industry and highlighted three stocks to outperform: TerrAscend (OTCQX:TRSSF), Green Thumb (OTCQX:GTBIF) and Cresco Labs (OTCQX:CRLBF).

READ FULL CANNABIS STOCKS ARTICLE

2. 3 Psychedelic Stocks to Buy for HUGE Gains in the Shroom Boom

Psychedelic Drugs Are Losing Their Negative Stigma, Paving the Way for Major Gains in Psychedelic Stocks

Today, psychedelics — like LSDMDMA and “Magic Mushrooms” — are on the cusp of a Shroom Boom, wherein psychedelic-inspired treatments will go from taboo to the mainstream. Against that backdrop, Psychedelic Stocks will roar higher. With that in mind, some of the best psychedelic stocks to buy for potentially huge gains are: MindMed (OTCQB:MMEDF), Champignon Brands (OTCQB:SHRMF), Revive Therapeutics (OTCPK: RVVTF).

READ FULL PSYCHEDELIC STOCKS ARTICLE

1. 7 Marijuana Stocks for an Election Day Boost

Cannabis Can Finally Roll Up Some Profits if November Brings a Blue Wave to Washington

Last month, Sen. Kamala Harris, the running mate of former Vice President Joe Biden, announced in a virtual town hall, “we will decriminalize the use of marijuana…” But will that be enough to save embattled Marijuana Stocks? Here are seven to buy now for a post-election bump: Curaleaf (OTCQX:CURLF), Canopy Growth (NYSE:CGC), Cronos Group (NASDAQ:CRON), Tilray (NASDAQ:TLRY), Innovative Industrial Properties (NYSE:IIPR), Charlottes Web (OTCQX:CWBHF) and Turning Point Brands (NYSE:TPB).

READ FULL MARIJUANA STOCKS ARTICLE

Photo by Shelby Ireland on Unsplash